Cagent Vascular Forges Strategic Partnership With 3comma Medical

Cagent Vascular Inc. is teaming up with 3comma Medical GmbH to foster the adoption of its Serranator PTA Serration Balloon Product line. Under the collaboration, 3comma will be the exclusive international (OUS) distributor in the European Union and MENA (Middle East, North Africa) regions for Cagent Vascular.

The expanded market distribution builds upon the Serranator’s commercial success and U.S. market growth. The Serranator is a therapeutic treatment for peripheral artery disease (PAD) and chronic limb threatening ischemia (CLTI).

“We are excited to join forces with 3comma to accelerate adoption in international markets,” Cagent Vascular Chief Commercial Officer Paul Wilson said. “Partnering with 3comma marks an exciting step forward in expanding global access to the Serranator portfolio and delivering cutting-edge solutions to patients around the world. 3comma’s deep commercial experience with peripheral vascular products and quality service will strengthen our commercial efforts to ensure we maximize growth opportunities and rapidly scale our presence to match international demand. We’re especially excited to make Serranator more accessible to physicians, providing them with a better tool to enhance patient care and drive improved outcomes.”

The Serranator and Serranator SL-PRO PTA Serration Balloon Catheters are U.S. Food and Drug Administration-cleared, novel balloons using stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000 times more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies with minimal recoil. By bringing a differentiated approach to vessel preparation, Cagent Vascular continues to support physicians in delivering optimal outcomes for patients with PAD and CLTI.

“We are thrilled to partner with Cagent Vascular and bring Serranator to physicians worldwide. Cagent’s commitment to delivering high-quality products for the treatment of PAD and CLTI will be a valuable addition to the institutions we serve,” 3comma CEO/Managing Partner Marc Paris stated. “By combining our comprehensive distribution capabilities with Cagent’s offerings, we aim to optimize PAD and CLTI treatment across the globe.”

Cagent Vascular aims to advance vascular care by delivering clinically effective solutions that improve patient outcomes. The company’s proprietary serration balloon technology is designed to optimize vessel preparation, enhance arterial expansion, and address challenging lesion morphologies in peripheral artery disease and chronic limb-threatening ischemia.